SGLT-2 inhibitors were always prescribed by 10.8% of cardiology professionals, while GLP-1 agonists were always prescribed by 8.8% for cardiometabolic diseases.
Cross-Sectional (n=250)
Yes
Despite proven efficacy, the adoption of SGLT-2 inhibitors and GLP-1 agonists in Saudi Arabian cardiology practice remains limited by familiarity gaps, high costs, and safety concerns, highlighting a need for enhanced clinical education.
Despite the proven efficacy of SGLT-2 inhibitors and GLP-1 agonists, their adoption in cardiology is limited by familiarity gaps, cost concerns, and safety issues. Enhanced education, better access to guidelines, and addressing cost barriers are crucial steps to improve the adoption of these medications in clinical practice.
Jamsheer et al. (Sat,) conducted a cross-sectional in Heart failure and cardiometabolic diseases (n=250). SGLT-2 inhibitors and GLP-1 agonists vs. none was evaluated on Prescription practices for SGLT-2 inhibitors and GLP-1 agonists. SGLT-2 inhibitors were always prescribed by 10.8% of cardiology professionals, while GLP-1 agonists were always prescribed by 8.8% for cardiometabolic diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: